Antidermatitic perspective of hydrocortisone as chitosan nanocarriers: An ex vivo and in vivo assessment using an NC/Nga mouse model

Zahid Hussain, Haliza Katas, Mohd Cairul Iqbal Mohd Amin, Endang Kumulosasi, Shariza Sahudin

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The aim of this study to administer hydrocortisone (HC) percutaneously in the form of polymeric nanoparticles (NPs) to alleviate its transcutaneous absorption, and to derive additional wound-healing benefits of chitosan. HC-loaded NPs had varied particle sizes, zeta potentials, and entrapment efficiencies, when drug-to-polymer mass ratios increased from 1:1 to 1:8. Ex vivo permeation analysis showed that the nanoparticulate formulation of HC significantly reduced corresponding flux [∼24 μg/(cm2 h)] and permeation coefficient (∼4.8 × 10-3 cm/h) of HC across the full thickness NC/Nga mouse skin. The nanoparticulate formulation also exhibited a higher epidermal (1610 ± 42 μg/g of skin) and dermal (910 ± 46 μg/g of skin) accumulation of HC than those associated with control groups. An in vivo assessment using an NC/Nga mouse model further revealed that mice treated with the nanoparticulate system efficiently controlled transepidermal water loss [15 ± 2 g/(m2 h)], erythema intensity (232 ± 12), dermatitis index (mild), and thickness of skin (456 ± 27 μm). Taken together, histopathological examination predicted that the nanoparticulate system showed a proficient anti-inflammatory and antifibrotic activity against atopic dermatitic (AD) lesions. Our results strongly suggest that HC-loaded NPs have promising potential for topical/transdermal delivery of glucocorticoids in the treatment of AD.

Original languageEnglish
Pages (from-to)1063-1075
Number of pages13
JournalJournal of Pharmaceutical Sciences
Volume102
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Chitosan
Hydrocortisone
Skin
Nanoparticles
Skin Absorption
Dermatitis
Erythema
Particle Size
Wound Healing
Glucocorticoids
Polymers
Anti-Inflammatory Agents
Control Groups
Water
Pharmaceutical Preparations

Keywords

  • Allergic contact dermatitis
  • Biodegradable polymers
  • Corticosteroids
  • Ex vivo permeation
  • In vitro model
  • In vivo efficacy
  • Nanoparticles
  • Percutaneous

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Antidermatitic perspective of hydrocortisone as chitosan nanocarriers : An ex vivo and in vivo assessment using an NC/Nga mouse model. / Hussain, Zahid; Katas, Haliza; Mohd Amin, Mohd Cairul Iqbal; Kumulosasi, Endang; Sahudin, Shariza.

In: Journal of Pharmaceutical Sciences, Vol. 102, No. 3, 03.2013, p. 1063-1075.

Research output: Contribution to journalArticle

@article{f948e6069c1049c2a5644e40d72b21aa,
title = "Antidermatitic perspective of hydrocortisone as chitosan nanocarriers: An ex vivo and in vivo assessment using an NC/Nga mouse model",
abstract = "The aim of this study to administer hydrocortisone (HC) percutaneously in the form of polymeric nanoparticles (NPs) to alleviate its transcutaneous absorption, and to derive additional wound-healing benefits of chitosan. HC-loaded NPs had varied particle sizes, zeta potentials, and entrapment efficiencies, when drug-to-polymer mass ratios increased from 1:1 to 1:8. Ex vivo permeation analysis showed that the nanoparticulate formulation of HC significantly reduced corresponding flux [∼24 μg/(cm2 h)] and permeation coefficient (∼4.8 × 10-3 cm/h) of HC across the full thickness NC/Nga mouse skin. The nanoparticulate formulation also exhibited a higher epidermal (1610 ± 42 μg/g of skin) and dermal (910 ± 46 μg/g of skin) accumulation of HC than those associated with control groups. An in vivo assessment using an NC/Nga mouse model further revealed that mice treated with the nanoparticulate system efficiently controlled transepidermal water loss [15 ± 2 g/(m2 h)], erythema intensity (232 ± 12), dermatitis index (mild), and thickness of skin (456 ± 27 μm). Taken together, histopathological examination predicted that the nanoparticulate system showed a proficient anti-inflammatory and antifibrotic activity against atopic dermatitic (AD) lesions. Our results strongly suggest that HC-loaded NPs have promising potential for topical/transdermal delivery of glucocorticoids in the treatment of AD.",
keywords = "Allergic contact dermatitis, Biodegradable polymers, Corticosteroids, Ex vivo permeation, In vitro model, In vivo efficacy, Nanoparticles, Percutaneous",
author = "Zahid Hussain and Haliza Katas and {Mohd Amin}, {Mohd Cairul Iqbal} and Endang Kumulosasi and Shariza Sahudin",
year = "2013",
month = "3",
doi = "10.1002/jps.23446",
language = "English",
volume = "102",
pages = "1063--1075",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Antidermatitic perspective of hydrocortisone as chitosan nanocarriers

T2 - An ex vivo and in vivo assessment using an NC/Nga mouse model

AU - Hussain, Zahid

AU - Katas, Haliza

AU - Mohd Amin, Mohd Cairul Iqbal

AU - Kumulosasi, Endang

AU - Sahudin, Shariza

PY - 2013/3

Y1 - 2013/3

N2 - The aim of this study to administer hydrocortisone (HC) percutaneously in the form of polymeric nanoparticles (NPs) to alleviate its transcutaneous absorption, and to derive additional wound-healing benefits of chitosan. HC-loaded NPs had varied particle sizes, zeta potentials, and entrapment efficiencies, when drug-to-polymer mass ratios increased from 1:1 to 1:8. Ex vivo permeation analysis showed that the nanoparticulate formulation of HC significantly reduced corresponding flux [∼24 μg/(cm2 h)] and permeation coefficient (∼4.8 × 10-3 cm/h) of HC across the full thickness NC/Nga mouse skin. The nanoparticulate formulation also exhibited a higher epidermal (1610 ± 42 μg/g of skin) and dermal (910 ± 46 μg/g of skin) accumulation of HC than those associated with control groups. An in vivo assessment using an NC/Nga mouse model further revealed that mice treated with the nanoparticulate system efficiently controlled transepidermal water loss [15 ± 2 g/(m2 h)], erythema intensity (232 ± 12), dermatitis index (mild), and thickness of skin (456 ± 27 μm). Taken together, histopathological examination predicted that the nanoparticulate system showed a proficient anti-inflammatory and antifibrotic activity against atopic dermatitic (AD) lesions. Our results strongly suggest that HC-loaded NPs have promising potential for topical/transdermal delivery of glucocorticoids in the treatment of AD.

AB - The aim of this study to administer hydrocortisone (HC) percutaneously in the form of polymeric nanoparticles (NPs) to alleviate its transcutaneous absorption, and to derive additional wound-healing benefits of chitosan. HC-loaded NPs had varied particle sizes, zeta potentials, and entrapment efficiencies, when drug-to-polymer mass ratios increased from 1:1 to 1:8. Ex vivo permeation analysis showed that the nanoparticulate formulation of HC significantly reduced corresponding flux [∼24 μg/(cm2 h)] and permeation coefficient (∼4.8 × 10-3 cm/h) of HC across the full thickness NC/Nga mouse skin. The nanoparticulate formulation also exhibited a higher epidermal (1610 ± 42 μg/g of skin) and dermal (910 ± 46 μg/g of skin) accumulation of HC than those associated with control groups. An in vivo assessment using an NC/Nga mouse model further revealed that mice treated with the nanoparticulate system efficiently controlled transepidermal water loss [15 ± 2 g/(m2 h)], erythema intensity (232 ± 12), dermatitis index (mild), and thickness of skin (456 ± 27 μm). Taken together, histopathological examination predicted that the nanoparticulate system showed a proficient anti-inflammatory and antifibrotic activity against atopic dermatitic (AD) lesions. Our results strongly suggest that HC-loaded NPs have promising potential for topical/transdermal delivery of glucocorticoids in the treatment of AD.

KW - Allergic contact dermatitis

KW - Biodegradable polymers

KW - Corticosteroids

KW - Ex vivo permeation

KW - In vitro model

KW - In vivo efficacy

KW - Nanoparticles

KW - Percutaneous

UR - http://www.scopus.com/inward/record.url?scp=84878157759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878157759&partnerID=8YFLogxK

U2 - 10.1002/jps.23446

DO - 10.1002/jps.23446

M3 - Article

C2 - 23303620

AN - SCOPUS:84878157759

VL - 102

SP - 1063

EP - 1075

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 3

ER -